Cabaletta Bio is trading 7.26% up at $1.39, amid new Phase 1/2 rese-cel results presented at ACR Convergence.
- The release was published November 8, ahead of Monday presentations, and did not attribute the share move to the results.
- Results showed durable, immunomodulator-free improvements across autoimmune diseases, with favorable safety findings in 71 patients.
- Shares closed at $1.30 November 6. Trading was live at 9:40 a.m. EST November 9; current volume and independent price attribution are unavailable.